Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox IND 103331) During Consolidation.

Trial Profile

Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox IND 103331) During Consolidation.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Arsenic trioxide (Primary) ; Cytarabine; Idarubicin; Mercaptopurine; Methotrexate; Mitoxantrone; Tretinoin
  • Indications Acute promyelocytic leukaemia
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 02 Aug 2017 Primary endpoint of event-free survival has been met, according to results published in the Journal of Clinical Oncology.
    • 02 Aug 2017 Results published in the Journal of Clinical Oncology
    • 13 Feb 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top